Overview

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

To compare the differential influence of 1st line doublet chemotherapy containing Docetaxel versus Pemetrexed on clinical efficacy of Erlotinib as a second line therapy in patients with relapsed or progressed non-squamous NSCLC.

Phase:

Phase 2

Details

Lead Sponsor:

Chang Gung Memorial Hospital

Collaborator:

Taiwan Chest Disease Association

Treatments:

Cisplatin
Docetaxel
Erlotinib Hydrochloride
Pemetrexed